Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.

ABSTRACT:

Background

Preclinical and clinical studies suggest that β₃ -adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This proof-of-concept study evaluated the efficacy and safety of the β₃ -adrenergic agonist vibegron in treating IBS-related pain.

Methods

Adult women with predominant-diarrhea IBS (IBS-D) or with mixed diarrhea/constipation (IBS-M), diagnosed using Rome IV criteria, were randomized 1:1 to receive once-daily vibegron 75 mg or placebo for 12 weeks. The primary endpoint was the percentage of patients with IBS-D considered abdominal pain intensity (API) weekly responders, defined as ≥30% reduction from baseline at week 12 in me

SUBMITTER: Lacy BE 

PROVIDER: S-EPMC10078113 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature